Ahead of its October 1, 2026 separation from Corteva, Vylor plans to launch four new soybean technology platforms by 2035, including advanced insect control and herbicide tolerance for Latin America and North America. These innovations aim to cover 95% of Vylor's soybean business, enhancing yields and licensing opportunities to secure global market leadership by mid-2030s. Vylor will also introduce first-generation products targeting Asian Soybean Rust and multi-disease resistance, expanding beyond herbicide and insect traits. This strategy leverages elite genetics and proprietary technology to maintain and grow Vylor's soybean dominance worldwide.
Vylor's planned soybean technology expansion coincides with a mixed US stock market on Pluang, where 48 of 150 priced stocks rose and 96 fell as of Sep 15, 2026 18:04 WIB. For readers following US equities, notable movers include COIN (Coinbase Global, Inc.) at USD 183.40, down 4.20%, NOK (Nokia Corp) at USD 10.00, up 3.57%, and XPEV (Xpeng Inc - ADR) at USD 10.41, down 2.80%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
